Previous close | 57.60 |
Open | 58.06 |
Bid | 54.06 x 100 |
Ask | 54.46 x 200 |
Day's range | 53.59 - 58.42 |
52-week range | 27.02 - 73.00 |
Volume | |
Avg. volume | 347,731 |
Market cap | 1.958B |
Beta (5Y monthly) | 1.32 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Financial Performance Misses Analyst Forecasts Amid Increased R&D Investments
Key Insights Keros Therapeutics' estimated fair value is US$93.42 based on 2 Stage Free Cash Flow to Equity Current...
Despite Higher Losses, KROS Advances Clinical Trials and Strengthens Cash Position